Outset Medical Inc (NASDAQ: OM) closed the day trading at $3.15 down -9.22% from the previous closing price of $3.47. In other words, the price has decreased by -$0.3200 from its previous closing price. On the day, 1056412 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of OM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.37 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 1.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on January 12, 2024, Downgraded its rating to Sector Perform and sets its target price to $6 from $14 previously.
On October 13, 2023, BofA Securities Downgraded its rating to Underperform which previously was Buy and also lowered its target price recommendation from $32 to $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 15 when Trigg Leslie sold 5,320 shares for $3.57 per share. The transaction valued at 18,992 led to the insider holds 833,091 shares of the business.
Ahmed Nabeel sold 4,403 shares of OM for $15,719 on Feb 15. The Chief Financial Officer now owns 312,594 shares after completing the transaction at $3.57 per share. On Feb 15, another insider, Brottem John L., who serves as the General Counsel of the company, sold 3,341 shares for $3.57 each. As a result, the insider received 11,927 and left with 245,046 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OM now has a Market Capitalization of 175.25M and an Enterprise Value of 108.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.22 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 0.83 whereas that against EBITDA is -0.70.
Stock Price History:
Over the past 52 weeks, OM has reached a high of $24.13, while it has fallen to a 52-week low of $2.73. The 50-Day Moving Average of the stock is 4.2264, while the 200-Day Moving Average is calculated to be 11.1210.
Shares Statistics:
Over the past 3-months, OM traded about 900.96K shares per day on average, while over the past 10 days, OM traded about 719.18k shares per day. A total of 50.32M shares are outstanding, with a floating share count of 46.54M. Insiders hold about 7.85% of the company’s shares, while institutions hold 105.23% stake in the company. Shares short for OM as of Feb 15, 2024 were 8.02M with a Short Ratio of 8.90, compared to 8.14M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.88% and a Short% of Float of 18.68%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.54 for the current quarter, with a high estimate of -$0.44 and a low estimate of -$0.62, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.46 and low estimates of -$0.59.
Analysts are recommending an EPS of between -$1.95 and -$2.18 for the fiscal current year, implying an average EPS of -$2.06. EPS for the following year is -$1.8, with 6 analysts recommending between -$1.65 and -$1.99.
Revenue Estimates
6 analysts predict $30.45M in revenue for the current quarter. It ranges from a high estimate of $31M to a low estimate of $29.6M. As of the current estimate, Outset Medical Inc’s year-ago sales were $31.76M, an estimated decrease of -4.10% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $33.71M, a decrease of -6.50% less than the figure of -$4.10% in the same quarter last year. There is a high estimate of $35.8M for the next quarter, whereas the lowest estimate is $32M.
A total of 7 analysts have provided revenue estimates for OM’s current fiscal year. The highest revenue estimate was $150.1M, while the lowest revenue estimate was $145.73M, resulting in an average revenue estimate of $148.42M. In the same quarter a year ago, actual revenue was $130.38M, up 13.80% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $173.92M in the next fiscal year. The high estimate is $179M and the low estimate is $165.7M. The average revenue growth estimate for next year is up 17.20% from the average revenue estimate for this year.
